Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 8/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8028665 | 0.88 | ADRA1A (0.36) | ADRA1AROCK1CYP1A2CYP2D6HTR2C | |
| SCHEMBL2062166 | 0.82 | BTK (0.30) | — | |
| SCHEMBL8035211 | 0.82 | — | — | |
| SCHEMBL8032869 | 0.78 | AVPR1A (0.41) | ADRA1AADRA2AAVPR1A | |
| SCHEMBL14996183 | 0.77 | CYP11B2 (0.38) | CYP1A2CYP2D6HTR2CHTR2BAVPR1A | |
| SCHEMBL13002467 | 0.70 | CYP11B2 (0.41) | CYP1A2CYP2D6HTR2CHTR2BAVPR1A | |
| SCHEMBL13002481 | 0.69 | ROCK1 (0.35) | ROCK1CYP1A2CYP2D6HTR2CHTR2B | |
| Trifluoroacetic Acid SCHEMBL3760442 | 0.68 | CYP11B1 (0.34) | KCNH2 | |
| SCHEMBL8019235 | 0.68 | GABRG2 (0.37) | CYP1A2CYP2D6 | |
| SCHEMBL14996186 | 0.67 | CYP11B2 (0.42) | CYP1A2CYP2D6HTR2CHTR2BAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250157-B1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-8455479-B2 | Heterocyclic compounds | PANACEA BIOTEC LIMITED (IN) | 2013-06-04 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| WO-2009093269-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | ADRA1A 1704/4885ROCK1 3161/4885CYP1A2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.